{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T11:07:38Z","timestamp":1768475258370,"version":"3.49.0"},"reference-count":20,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2014,5,22]],"date-time":"2014-05-22T00:00:00Z","timestamp":1400716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Urologia"],"published-print":{"date-parts":[[2014,10]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p> We aimed to evaluate the long-term recurrence and progression rates in a Turkish population with high-grade Ta and T1 bladder cancer and to determine malign potential of high-grade Ta bladder cancer. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p> 191 patients who had non-invasive bladder cancer were evaluated at a single institution between 2005 and 2010. Median follow-up was 55.6 months (13-108). Long-term follow-up results of recurrence and progression rates of high-grade Ta and T1 were analyzed and compared with each other. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Of the 191 patients, 143 (74.9%) were high-grade T1 and 48 (25.1%) were high-grade Ta. Of the 143 patients who were high-grade T1, 39 (27.2%) responded to the induction BCG without recurrence. 33 (23%) patients had invasion deep into the muscle layer. 61 (42%) patients had recurred as high-grade T1. Of the 48 patients who were high-grade Ta, 15 (31%) responded to induction BCG without recurrence. 18 (37.5%) patients had recurrence as high-grade Ta. 12 (25%) patients had invasion deep into to the muscle layer. Of all the patients, 13 (7%) patients died of causes related to bladder cancer. In a multivariate analysis, concomitant CIS was statistically significant for the progression of high-grade Ta bladder cancer (p&lt;0.005). <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p> According to the data of the current study, the presence of concomitant CIS in patients with high-grade bladder cancers is associated with a higher risk of progression. There is a need for larger scale multi-institutional studies in order to support the hypothesis that high-grade Ta tumors should be considered as T1 tumors. <\/jats:p><\/jats:sec>","DOI":"10.5301\/uro.5000072","type":"journal-article","created":{"date-parts":[[2014,7,21]],"date-time":"2014-07-21T09:53:59Z","timestamp":1405936439000},"page":"237-241","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Analysis of Results of Recurrence and Progression Rates of High-Grade Ta Bladder Cancer and Comparison with Results of High-Grade T1"],"prefix":"10.1177","volume":"81","author":[{"given":"Muhammet Fatih","family":"Kilinc","sequence":"first","affiliation":[{"name":"Ankara Training and Research Hospital, Ankara - Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurettin Cem","family":"Sonmez","sequence":"additional","affiliation":[{"name":"Urology Department, Sisli Etral Training and Research Hospital, Istanbul - Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayhan","family":"Dalkilic","sequence":"additional","affiliation":[{"name":"Urology Department, Sisli Etral Training and Research Hospital, Istanbul - Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serdar","family":"Arisan","sequence":"additional","affiliation":[{"name":"Urology Department, Sisli Etral Training and Research Hospital, Istanbul - Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soner","family":"Guney","sequence":"additional","affiliation":[{"name":"Urology Department, Sisli Etral Training and Research Hospital, Istanbul - Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2014,5,22]]},"reference":[{"key":"bibr1-uro.5000072","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-009-0383-3"},{"key":"bibr2-uro.5000072","first-page":"1731","volume":"11","author":"Eser S","year":"2010","journal-title":"Pac J Cancer Prev"},{"issue":"1","key":"bibr3-uro.5000072","first-page":"31","volume":"10","author":"Pasin E","year":"2008","journal-title":"Rev Urol"},{"key":"bibr4-uro.5000072","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.240501307"},{"key":"bibr5-uro.5000072","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.06.135"},{"key":"bibr6-uro.5000072","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67975-X"},{"key":"bibr7-uro.5000072","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)36926-4"},{"key":"bibr8-uro.5000072","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67972-4"},{"key":"bibr9-uro.5000072","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.03.052"},{"key":"bibr10-uro.5000072","doi-asserted-by":"publisher","DOI":"10.1016\/S0094-0143(03)00060-0"},{"key":"bibr11-uro.5000072","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(03)00040-X"},{"key":"bibr12-uro.5000072","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2003.12.016"},{"key":"bibr13-uro.5000072","doi-asserted-by":"publisher","DOI":"10.1089\/end.2008.0281"},{"key":"bibr14-uro.5000072","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000070437.14275.e0"},{"key":"bibr15-uro.5000072","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(01)01522-9"},{"key":"bibr16-uro.5000072","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10654.x"},{"key":"bibr17-uro.5000072","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)66443-9"},{"key":"bibr18-uro.5000072","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67973-6"},{"key":"bibr19-uro.5000072","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64273-5"},{"key":"bibr20-uro.5000072","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64043-8"}],"container-title":["Urologia Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.5301\/uro.5000072","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.5301\/uro.5000072","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.5301\/uro.5000072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T08:42:34Z","timestamp":1740904954000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.5301\/uro.5000072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,22]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["10.5301\/uro.5000072"],"URL":"https:\/\/doi.org\/10.5301\/uro.5000072","relation":{},"ISSN":["0391-5603","1724-6075"],"issn-type":[{"value":"0391-5603","type":"print"},{"value":"1724-6075","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,22]]}}}